Top Pharma News - IgeaHub

Top Pharma News of the Week

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine August 16, 2017 Amgen has announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER). The … Continue reading Top Pharma News of the Week

Top 20 Drugs in the World 2017

Top 20 Drugs in the World 2017

The global prescription drug market is expected to grow by 6% from 2016 to 2022 to reach nearly USD 1.05 trillion by 2022. The top 20 drugs are manufactured by 14 companies and account for a total 10% of global prescription drug market in 2016. The total revenue generated by top 20 products was estimated … Continue reading Top 20 Drugs in the World 2017

Top Pharma News - IgeaHub

Top Pharma News of the Week

Amgen Submits Supplemental Biologics License Application for Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis  July 31, 2017 Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA is based on a Phase 3 study evaluating the … Continue reading Top Pharma News of the Week

Top Pharma News - IgeaHub

Top Pharma News | July – August 2017

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint July 5, 2017 Bristol-Myers Squibb Company has announced that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its … Continue reading Top Pharma News | July – August 2017

Top Pharma News - IgeaHub

Top Pharma News of the Week

Amgen and Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation July 18, 2017 Amgen and Array BioPharma have announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development. EU … Continue reading Top Pharma News of the Week

Top News from EHA 2017 Congress

AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) June 23, 2017 AbbVie has announced the presentation of results from the pivotal Phase 2 study of VENCLYXTO™ (venetoclax), a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor. VENCLYXTO monotherapy responses in 158 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) … Continue reading Top News from EHA 2017 Congress

Top Pharma News - IgeaHub

Top Pharma News of the Week

Seattle Genetics gets a PhIII win for Adcetris June 26, 2017 Seattle Genetics says that its flagship therapy, Adcetris, combined with a trio of standard drugs beat a 4-drug mainstay cocktail therapy in frontline Hodgkin disease for modified progression-free survival over a lengthy two-year stretch. The Adcetris package excluded bleomycin, which has been linked to … Continue reading Top Pharma News of the Week

Amgen Logo

Amgen Submits Applications in the US and Europe for Expanding Current Indication For XGEVA (denosumab) to Include Patients with Multiple Myeloma

April 4, 2017 Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to the European Medicines Agency (EMA) for XGEVA® (denosumab). These submissions to regulatory authorities seek to expand the currently approved XGEVA indication for the prevention of skeletal-related events … Continue reading Amgen Submits Applications in the US and Europe for Expanding Current Indication For XGEVA (denosumab) to Include Patients with Multiple Myeloma

Top Pharma News - IgeaHub

Top Pharma News | February – March 2017

Amgen Announces the Efficay of Repatha® (Evolocumab) for Reducing the Risk of Cardiovascular Events February 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, … Continue reading Top Pharma News | February – March 2017

World's Most Admired Pharmaceutical Companies 2017

World’s Most Admired Pharmaceutical Companies 2017

Reputation is extremely important for Pharmaceutical Companies. Like every year, Fortune collaborated with Korn Ferry Hay Group on the survey of corporate reputations. To determine the best-regarded companies in 51 industries, Korn Ferry Hay Group evaluated 680 companies in 28 countries. Executives, directors, and analysts have been asked to rate enterprises in their own industry, here … Continue reading World’s Most Admired Pharmaceutical Companies 2017